New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

OhhMed Medical Ltd., a pioneering medical technology firm specialising in male urology, today announced the initiation of a ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.

In patients with a high suspicion of prostate cancer as determined by molecular imaging, avoiding biopsy prior to radical prostatectomy appeared to be feasible, and "might represent a valid option in ...

Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy.

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Up to 72% of patients with prostate cancer who undergo radical prostatectomy experience urinary incontinence in the first 3 months after surgery. Up to 72% of patients experience urinary incontinence ...

Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027.